TGFβRI-IN-3
TGFβRI-IN-3 inhibits TGFβR1 at an IC50 of 0.79 nM with 2000-fold selectivity against MAP4K4. TGFβRI-IN-3 represents a highly selective TGFβR1 inhibitor that has potential applications in immuno-oncology[1].
Product Specifications
CAS Number
[2763602-67-9]
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
TGF-β Receptor
Type
Reference compound
Related Pathways
TGF-beta/Smad
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/tgfβri-in-3.html
Purity
98.21
Solubility
DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
CS(C1=CC=C(C=C1)C2=CC=C3C(NC4=CC=NC(C5=CC(C)=CC=C5)=C4)=CC=NC3=C2)(=O)=O
Molecular Formula
C28H23N3O2S
Molecular Weight
465.57
Precautions
H302, H315, H319
References & Citations
[1]Kharbanda A, et al. Discovery of 4-aminoquinolines as highly selective TGFβR1 inhibitors with an attenuated MAP4K4 profile for potential applications in immuno-oncology [published online ahead of print, 2021 Aug 12]. Eur J Med Chem. 2021;225:113763.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
QP6237-ec-1mg 1mg
Recombinant Human Intestine-specific homeobox Protein, His-SUMO, E.coli-1mg
Ask
View Details 043504-AP 200 µL
UBA7, NT (UBA7, UBE1L, UBE2, Ubiquitin-like modifier-activating enzyme 7, D8, Ubiquitin-activating enzyme E1 homolog) (AP) discontinued
Ask
View Details